Implementation Engineer, Proscia
EMEA
Rewiring pathology for precision medicine
Open for applications
Rewiring pathology for precision medicine
101-200 employees
Open for applications
101-200 employees
Company mission
To accelerate pathology's transition from microscope to images, and to use that data to change the way we think about cancer.
Jump to section
Company mission
To accelerate pathology's transition from microscope to images, and to use that data to change the way we think about cancer.
-13% employee growth in 12 months
Our take
Data suggests that whilst the number of people with cancer is expected to rise by 47% by 2040, the number of pathologists in the United States will decline by 17.53%. For this reason, there is a need to digitize pathology. Proscia uses computing, visualization and machine learning to aid pathologists towards diagnosing cancers.
Proscia is very well positioned in the explosive medicine market with its services currently being used by 16 of the top 20 pharmaceutical companies. The company has successfully developed algorithms using commercially available technology that reaches ‘substantial agreement’ with the human read, thereby cementing itself as a rare and much needed solution to the declining access to human pathologists.
Previous funding rounds saw Proscia launch new products, such as an automated quality control application that improves the efficiency of data-driven drug development. And new 2025 capital will accelerate the broader adoption ofits AI-powered pathology platform, allowing Proscia to weave AI more deeply into core workflows, expand its reach across pharmaceutical and diagnostic organizations, and help pathologists deliver faster, more precise insights at scale.
Steph
Company Specialist at Welcome to the Jungle
Benefits
- Medical, dental, vision insurance
- Unlimited PTO
- Retirement plan options
- Commuter benefits
- Company sponsored short- and long-term disability plans
Funding (last 2 of 7 rounds)
Mar 2025
$50m
LATE VC
Mar 2024
$9m
SERIES C
Total funding: $129.3m
This company has top investors
Leadership
Coleman Stavish
(Co-Founder & CTO)Previously worked as an Independent iOS Developer before joining Bombardier Transportation as a Software Engineering Co-op.
David West
(Co-Founder & CEO)Prior to co-founding Proscia, received a Bachelor of Science in Bioengineering and Biomedical Engineering from The Johns Hopkins University.
Nathan Buchbinder
(Co-Founder & CSO)Previously co-invented Design Team: The Cooling Cure and has been a Team Leader for Biliary and Pulmonary Brush Biopsy and Sleep Apnea Monitor Development.